Hot Stocks

Hot stocks are not about hype. They emerge when powerful themes, policy shifts, and capital flows converge. InvestorPlace analysts track fast-moving market narratives, especially in technology, AI, and infrastructure, to identify stocks drawing outsized attention and explain what is really driving those moves.

Slumping Industry Group Rank Keep Schlumberger (SLB) a Sell

By Portfolio Grader
Schlumberger NV (NYSE:SLB) is one of 73 companies within the Energy Equipment & Services GICS industry group, which is in turn part of the 362 company GICS Energy sector. SLB's market value is $89.7 billion which falls in the top decile in its industry group. The ranking for SLB by Portfolio Grader places it 53 among the 73 companies in this industry group, giving it a lower than average position; squarely in the bottom quartile of the sector with a ranking of 295 among the 362 companies in the sector, and number 4,223 in the nearly 5,000 company Portfolio Grader universe.

My Target on Target Corporation Stock: Lower, Lower, Lower

By Lawrence Meyers, InvestorPlace Contributor
TGT stock offers a nice dividend, but Target Corporation isn't growing and the company insists on spending money foolishly.

Solid Quant Score Keep Eli Lilly (LLY) a Buy

By Portfolio Grader
Eli Lilly and Company (NYSE:LLY) is ranked as a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking LLY has had from Portfolio Grader for the last month.

Teva Pharmaceutical Stock Surges on Job Cuts Talk

By William White, InvestorPlace Writer
Teva Pharmaceutical (TEVA) stock was on its way up today on talk that the company is looking to reduce its cost by cutting jobs.

Earnings Visibility Make NTT Docomo (DCM) a Buy

By Portfolio Grader
NTT Docomo Inc (NYSE:DCM) is one of the 65 companies in the GICS Telecommunication Services sector, and a member of the 21 company Wireless Telecommunication Services GICS industry group within this sector. DCM's market value is $95.0 billion which falls in the top decile in its industry group. The ranking for DCM by Portfolio Grader places it 7 among the 21 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 17 among the 65 companies in the sector, and number 800 in the nearly 5,000 company Portfolio Grader universe.

Quant Score Keeps Novo Nordisk A/S (NVO) Shares a Buy

By Portfolio Grader
As one of the 782 companies in the GICS Health Care sector Novo Nordisk A/S (NYSE:NVO) is a constituent of the 134 company Pharmaceuticals GICS industry group within this sector. NVO has a market value of $102.0 billion which is in the top 10% of its industry group. Portfolio Grader's current ranking for NVO puts it 14 among the 134 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 110 among the 782 companies in the sector, and number 634 in the nearly 5,000 company Portfolio Grader universe.

Bristol-Myers Squibb Co (BMY) Industry Group Rank Penalize Rating

By Portfolio Grader
Bristol-Myers Squibb Co (NYSE:BMY) is a $103.5 billion in market value constituent of the Pharmaceuticals GICS industry group where Portfolio Grader's current ranking for BMY puts it 64 among the 134 companies in this industry group, placing it in the top half. BMY is ranked in the top half of the sector with a ranking of 370 among the 782 companies in the sector and number 2,185 in the 5000 company Portfolio Grader company universe.

Is Tax Reform Already Priced In?

By John Jagerson and Wade Hansen
With the S&P 500 near its all-time high, it’s hard to make the argument that some of the anticipated impacts of tax reform aren't already priced into the market.

Sanofi (SNY) a Hold on Vapid Earnings Momentum

By Portfolio Grader
Sanofi SA (NYSE:SNY) is a constituent of the 134 company Pharmaceuticals GICS industry group, which is a segment of the 782 company GICS Health Care sector. SNY's market value is $112.1 billion which places it in the top 10% of its industry group. Portfolio Grader's current ranking for SNY puts it 53 among the 134 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 307 among the 782 companies in the sector, and number 1,707 in the nearly 5,000 company Portfolio Grader universe.

Analytics for Quant Score Drive Upgrade of Motif Bio (MTFB) to Buy

By Portfolio Grader
Motif Bio Plc (NULL:MTFB) is ranked as a Buy using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methodology. The shares have been upgraded from a Hold to a Buy in the last week.

BP (BP) Shares a Buy on Quant Score

By Portfolio Grader
BP Plc (NYSE:BP) is one of the 362 companies in the GICS Energy sector, and a member of the 289 company Oil Gas & Consumable Fuels GICS industry group within this sector. BP's market value is $131.8 billion which falls in the top decile in its industry group. The stock's current Portfolio Grader score places it 19 among the 289 companies in this industry group, positioning it among the leaders; among the sector leaders with a ranking of 19 among the 362 companies in the sector, and number 754 in the nearly 5,000 company Portfolio Grader universe.

Total (TOT) a Buy on Solid Earnings Growth

By Portfolio Grader
Total SA (NYSE:TOT) is ranked as a Buy using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. TOT has recently seen its Portfolio Grader rating downgraded over the last month from a Strong Buy to a Buy.

Best-in-Class Sales Growth Keeps Royal Dutch Shell (RDS.A) a Strong Buy

By Portfolio Grader
Currently, Royal Dutch Shell Plc (NYSE:RDS.A) has a Strong Buy using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methodology. RDS.A has maintained this ranking for 4 months.

Is Bitcoin a Bubble Waiting to Pop?

By InvestorPlace Research Staff
If bitcoin is a bubble, and the cryptocurrency falls back to $5000, I would aggressively buy bitcoin in anticipation of a much larger rally.

Merck & Co (MRK) a Sell on Adverse Earnings Momentum

By Portfolio Grader
Portfolio Grader currently ranks Merck & Co (NYSE:MRK) a Sell. The methodology for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. MRK has maintained this ranking for 2 months.

DowDuPont (DWDP) Sees Rating Decline….. Weak Quant Score

By Portfolio Grader
DowDuPont Inc (NULL:DWDP) is one of 96 companies within the Chemicals GICS industry group, which is in turn part of the 266 company GICS Materials sector. DWDP's market value is $166.1 billion which places it in the top decile in its industry group. Portfolio Grader's current ranking for DWDP puts it 43 among the 96 companies in this industry group, giving it an above-average position; in the top half of the sector with a ranking of 129 among the 266 companies in the sector, and number 2,140 in the nearly 5,000 company Portfolio Grader universe.

Novartis AG (NVS) a Buy on High-Level Quant Score

By Portfolio Grader
Novartis AG (NYSE:NVS) is a member of the 134 company Pharmaceuticals GICS industry group, which is part of the 782 company GICS Health Care sector. NVS's market value is $200.3 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for NVS puts it 15 among the 134 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 109 among the 782 companies in the sector, and number 639 in the nearly 5,000 company Portfolio Grader universe.

Weak Earnings Growth Hamper China Mobile (CHL) Rating

By Portfolio Grader
Currently, China Mobile Ltd (NYSE:CHL) has a Hold using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. CHL has recently seen its Portfolio Grader rating downgraded over the last month from a Buy to a Hold.

How the iPhone’s Success Weakens Apple Inc. Stock

By Vince Martin, InvestorPlace Contributor
Apple's reliance on the iPhone has gotten it this far. But concerns about "commoditization" and lengthening product cycles still pose a long-term risk.
Load More Articles